Crystal Phend

Crystal Phend is a senior associate editor at MedPage Today. She covers cardiology news as well as other developments in medicine. Crystal is known for her clear and unbiased reporting.

Biography:  https://www.medpagetoday.com/authors/crystalphend

92%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

80%

Examples:

  • In the article 'Lowering the Target for Blood Pressure Is Best, Study Affirms', the author disclosed funding from China's Ministry of Science and Technology for the trial and from Servier (Tianjin) Pharmaceutical, Lilly, and BioValley.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

New Study: Semaglutide in Ozempic Reduces Risk of Serious Kidney Outcomes, Major Cardiovascular Events, and Death for Diabetes Patients with Chronic Kidney Disease

New Study: Semaglutide in Ozempic Reduces Risk of Serious Kidney Outcomes, Major Cardiovascular Events, and Death for Diabetes Patients with Chronic Kidney Disease

Broke On: Friday, 24 May 2024 New findings from the FLOW trial show semaglutide, a compound in Ozempic, reduces risk of serious kidney outcomes, major cardiovascular events and death for diabetes patients with chronic kidney disease.

Recent Studies Highlight New Approaches and Insights in Blood Pressure Management

Broke On: Tuesday, 14 November 2023 Chronic insufficient sleep can increase insulin resistance in healthy women, particularly postmenopausal women. Alnylam Pharmaceuticals has developed an RNA interference treatment, zilebesiran, which has shown to reduce blood pressure for six months with one to two doses in a mid-stage clinical trial. Reducing sodium intake can help lower blood pressure as effectively as medication. A systolic blood pressure treatment target under 120 mm Hg improves outcomes and saves lives compared with a threshold of 140 mm Hg for higher risk patients with hypertension.